Table 1.
Treatments | Studies per treatment arm | Studies tested the trt with AL | Total sample size | Nbr of ACPR | % of ACPR |
---|---|---|---|---|---|
AL | 63 | – | 12,981 | 11,426 | 88 |
AQSP | 12 | 7 | 2681 | 1731 | 64.56 |
ASAQ | 42 | 31 | 8254 | 7402 | 89.6 |
ASAQCPH | 1 | 1 | 54 | 47 | 87.03 |
ASATPG | 1 | 0a | 100 | 95 | 95 |
ASCD | 4 | 4 | 1591 | 1326 | 83.3 |
ASMQ | 6 | 5 | 843 | 800 | 94.89 |
ASNAPH | 2 | 2 | 147 | 144 | 97.95 |
ASPY | 2 | 2 | 1204 | 1105 | 91.77 |
ASSMP | 4 | 3 | 1545 | 1461 | 94.5 |
ASSP | 11 | 3 | 1752 | 1593 | 91 |
DHAP | 22 | 18 | 6182 | 4969 | 80.3 |
DHAPT | 1 | 1 | 212 | 204 | 96.2 |
Data were extracted for all studies. The combination AL was the most frequently evaluated drug combination within the data. Few studies tested novel combinations. There was no study comparing ASATPG directly to AL
Nbr number, trt treatment, ACPR adequate clinical and parasitological response corrected by PCR